OS
OneStream, Inc. Class A Common Stock
stock NASDAQ

I have now made and use programs that auto-retry seeds and find vanity addresses. This might sound good but the issue is that it finds too many so the real mission is to go for many retries until a single one is found, instead of thousands of low-character addresses. I didn't deploy these for SOL yet since I'm still testing attacks on myself with dummy wallets.
Using OS date and time is inadequate for RNG in my opinion. If a computer creates RNG in some other way, I don't know what that is. I need some code that creates something I can be more sure cannot be replicated so when I finally hit a good seed, I can be sure no one else has it. Once I hit it, I would even format the computer.
Do not say to ask ChatGPT because it uses outdated modules for imports and pretends it followed instructions when it did not.
Is there anything that VanitySearch does that adds layers of safety to someone doing this by themselves? Ignore everything it does for compatibility and speed. I'm not a dev, so I don't even know the purpose of the array/matrix under its static constant.

They have no choice and the ROI is good for most of them even if they don't make a cent.
This is about staying relevant and not being replaced. Google doesn't want to lose it's position as search engine that make them 200B+ a year. They don't want openAI or perplexity to replace them. It is a well worth to invest a few hundred billions over a few years. The best for them maybe is that AI is a flop and they stay leader. But they can't take the risk and do nothing.
For Microsoft it all the same. They want to stay relevant for their OS and office software and to offer good cloud capabilities. So they have to invest.
Meta, Apple and all the others don't want to be replaced and they can afford the expense. So they all go all in.
openAI is different because they make no money but their situation is worse. if they don't success they go bankrupt. So they burn all the investor money they can trying to outsmart the others. Same for many startup.
They behavior make lot of sense, really.

Isn't the OS about to double lol? I accepted my losses and moved on. There are so many great opportunities to invest in out there. Why miss out on all these 1000% runners over the past year. End of the day it's your money at risk. AMC doesn't care about. This subreddit doesn't care about you. Protect yourself and your own capital.

I have a Google workspace subscription for a personal business and there still is a lot to be desired for Gemini integration. I think Microsoft has the clearer path forward there as Google has no OS level access.
As a software engineer in my day job Claude code is still the standard for agentic coding, largely because it has low level access to the cli

Price Target and Ratings from Market Beat
Average Price Target for OS Therapies$18.00
High Price Target$20.00
Low Price Target$15.00
Potential Upside/Downside+804.5%
Consensus RatingBuy
Rating Score (0-4)3.00
Research Coverage

lol you can go back to our previous chats and I was clear
This so called “bull market” I don’t see doge coin going above 50 cents and it will be a challenge to break 35 cents
You shot me down with all your word salads, previous speculations etc etc and here we are in Q4 of a “bull market” while every other coin in the top 10 is making new ATH. Doge can’t even break 30 cents, even with all etf news (which I don’t support, just buy the coin)
Doge OS,such pay,”house of doge” aka house of rubbish etc etc. real world use that would generally be a good indicator of being bullish but yet real world investors don’t care. They continue to pump and dump it
We spoke about this and you still called me names or whatever
Granted the bull run isn’t over but me personally I don’t see doge getting over 50 cents on an alt season or etf news alone
If you can list and prove me otherwise
Go ahead
Other than that it will continue to trade like a meme coin and never move as it should
With all the good news surrounding doge it should be much higher in price

You still here? Didn’t you say doge will outshine everyone this fall? Or something along those lines
Don’t deny it. You kept hyping it up and attacking me cause I don’t share the same joy you do about this coin and see that nobody cares about it
It’s a meme coin plain and simple
Doge OS,ETF’s,doge rockets,doge treasury etc etc
People don’t care about its real world use
And which doge is prob one of only a few cryptos that does it
Nah people would rather long and short it all day
That’s why it’s never going to go anywhere without an Elon hype or tweet
I can’t wait to get rid of this silly coin

All OS vendors should brick any computer on a Chinese IP.

I’ve got my first-stage technical interview with IMC Trading coming up soon, and I can’t find much info online about what to expect. The portal says to review “key technical concepts related to the role such as programming languages, system design, and relevant tools.”
Right now, I’m focusing on -
OS concepts: concurrency, virtualization from OS STEP
DSA: basics (arrays, linked lists, stacks, queues), graphs, 1D/2D DP, sorting algorithms with time complexities maybe heap, etc.
C++ features: memory management, pointers/references, copy vs move semantics, and OOP
If anyone has gone through their interview recently, could you share what kind of questions they ask or what areas are worth focusing on?
Any valuable suggestion would really help!

I wonder if theres any advantage to using an OS this old

Interesting, I might look into it.
Don't you just love OS? I was an early adopter; someone on one of these forums developed it, and I had a little bit of early input. I still use it weekly at least, though not to the level you're talking here.
Thanks!

US and Israel are allied. Of course Israel has a way to control an OS from the US and vice versa. It's really not about actually hacking the device they can just take a visit to Apple (designed in California) and add their backdoors.

# $GPUS - Price Target : $4.00 (8x)
What is GPUS?
Hyperscale Data is in the middle of a transformation — moving from a broad holding structure to a focused operator in AI data infrastructure and digital asset mining. They own a massive 617,000 sq ft facility (on \~34.5 acres) in Michigan, currently being expanded for dual use:
* *High-Performance Computing (AI / HPC) workloads*
* *Bitcoin mining operations*
Their subsidiaries include Sentinum Inc. (for hosting, colocation, and mining) and Ault Capital Group, which they plan to spin off to streamline operations around core infrastructure.
Recent Developments & Catalysts
* *Debt Reduction (\~$30M):* GPUS just eliminated around $30 million in non-affiliated debt. That’s huge for a company this size — it frees up capital and improves the balance sheet for expansion and investor confidence.
* *AI + Bitcoin Infrastructure Expansion:* The Michigan facility is being upgraded to support enterprise-grade AI compute and high-efficiency mining. Power capacity expansion is already underway.
* *New Mining Fleet:* They’ve ordered 1,000 Bitmain Antminer S21s, with a plan to scale up to 5,000 units (≈20MW capacity). All mined BTC will be held on balance sheet as part of a long-term $100M Bitcoin treasury strategy.
*For context: the entire company’s market cap is around $12M, less than 1/8 of their target Bitcoin holdings alone. The math is easy.*
*Why It Matters*
* *Cleaner Balance Sheet*: debt elimination gives them room to reinvest and scale faster.
* *Dual Focus Model*: combining AI hosting + mining provides two strong revenue streams that hedge each other.
* *Scalability*: The infrastructure is already in place, expansion just adds throughput and recurring cash flow potential.
If management executes on their stated goals, completing the Michigan expansion, scaling miners, and growing hosting revenue, it’s not unrealistic to see a significant re-rating in 2025. Even partial progress could justify a multi bagger move from current levels, given the current valuation disconnect.
# $INTS - Price Target: $1.80 (6x)
What is INTS?
Intensity Therapeutics (NASDAQ: INTS) is a late-stage clinical biotech developing intratumoral cancer therapiesusing its DfuseRx℠ platform. Lead asset INT230-6 combines cisplatin + vinblastine with a proprietary amphiphile (“SHAO”) to disperse chemo throughout a tumor after direct injection, killing local disease and triggering systemic immune activation. 
Recent Developments & Catalysts
* Phase 3 (STS) – INVINCIBLE-3: Global, randomized OS-endpoint study of INT230-6 monotherapy vs SOCin 2L/3L soft-tissue sarcoma. DMC authorized continuation (Jan 28, 2025); new site activations/enrollment paused in Mar 2025 due to funding, with already-enrolled patients continuing; plan to restart when funded. 
* Phase 2 (TNBC) – INVINCIBLE-4: Presurgical TNBC study testing INT230-6 before SOC immunochemotherapy vs SOC alone; pCR is the primary endpoint; recruiting in Switzerland & France. Early scans showed marked necrosis within 8 days post-injection; pCR readouts expected 2H 2026.
* Compelling earlier data: Phase 1/2 in sarcoma/solid tumors showed mOS 21.3 months for INT230-6 monotherapy vs 6.7 months synthetic control, with T-cell activation and a favorable safety profile (hypothesis-generating but notable). 
* MPNST signal (preclinical): 100% complete responses in murine MPNST models—an intriguing rare-disease (orphan) angle for future development. 
* Checkpoint combo: Ongoing Merck KEYTRUDA® (pembrolizumab) collaboration exploring synergy in hard-to-treat solid tumors. 
* Balance sheet runway extended: Raised $6.6M via ATM in July 2025 (46.0M shares o/s post-ATM); in total >$11M since early Q2 2025, extending cash runway into 2H 2026. 
* Valuation context: Despite late-stage programs, market cap \~$15–16M (Oct 10, 2025)—micro-cap levels that magnify outcome sensitivity. 
Why It Matters
* Mechanistic edge: DfuseRx achieves tumor saturation with localized chemo kill while releasing neoantigensto drive a systemic immune response—without the broad immunosuppression of IV chemo. If replicated in Phase 3, this could be practice-changing for STS and expandable to other solid tumors.
* Clinical de-risking breadcrumbs: Human data already indicate tumor necrosis and immune engagement, plus suggestive OS improvement vs synthetic controls—setting a rationale for success in randomized settings (with appropriate caution).
* Multiple shots on goal:
* STS (OS endpoint) provides a hard clinical outcome.
* TNBC (pCR) is tied to long-term benefit in prior chemo-IO frameworks (e.g., KEYNOTE-522background cited in the INVINCIBLE-4 registry). 
* IO combo path via Merck could broaden addressable tumors.
* Asymmetric setup: With a nano-cap base and late-stage readouts ahead, incremental funding, enrollment restart, or early efficacy signals can move the equity disproportionately. 
Bull Case Summary
If management secures funding and restarts INVINCIBLE-3 enrollment, delivers pCR uplift in INVINCIBLE-4, and leans into checkpoint combo data—while maintaining Nasdaq compliance and runway—then INTS could see a significant re-rating through 2026. Even partial wins (e.g., enrollment restart + early TNBC pathology signals or a non-dilutive partnership) could justify multi-bagger upside from today’s valuation given the platform + late-stageprofile. $MNTS - Price Target $5.00 (4x)
# $MNTS - Price Target $5.00 (4x)
What is MNTS?
Momentus Inc. (ticker **MNTS**) is a **commercial space infrastructure** company focused on **in-space transportation**, **hosted payloads**, and **in-orbit services**. 
Core capabilities and assets include:
* **Orbital Service Vehicles (OSVs)** — the “Vigoride” vehicle is intended to move satellites or payloads between orbits, provide servicing, and act as a platform for on-orbit operations.
* **Hosted payload business** — integrating third-party instruments or experiments onto their vehicles, so clients don’t need a full satellite. 
* **Strategic contracts & grants** — partnerships, R&D contracts (e.g. with NASA) to support technology development and validation. 
Thus, MNTS positions itself at the intersection of **space logistics / “space as infrastructure”** — the “middleman” that helps get satellites from point A to B, extend their life, or host payloads without requiring full satellite builds.
Recent Developments & Catalysts
* **NASA robotics contract**: MNTS recently won a contract under NASA’s Flight Opportunities program to study deploying advanced robotics systems in space. That triggered an immediate rally in the stock (50-70% intraday jump) 
* **Warrant inducement financing (\~$2.7M)**: The company arranged for previously issued warrants to be exercised, generating $2.7M in gross proceeds.
* **Multiple new Govt / NASA contracts announced**: On Oct 9, 2025, they announced a $2.5M NASA contract to test a novel thruster in space, plus a $5.1M NASA contract to support “advanced materials production in space.” 
* **Capital & liquidity moves**: Given low cash, these financing and contract wins are vital for survival and execution. 
These catalysts suggest the company is trying to punch above its weight in securing governmental validation and non-dilutive funding.
Why It Matters
* **Validation & de-risking**: Winning contracts with NASA / governmental agencies is a strong signal in the space sector. It helps validate their tech, improves credibility, and fosters further contract opportunities.
* **Leverage scaling potential**: The core value lies in their transportation / servicing infrastructure, which has high operating leverage: once hardware and systems are proven, additional missions and payloads scale revenue without proportional cost increases.
* **Undervalued vs potential**: The current market cap is in the low tens of millions, while a single successful OSV deployment or recurring client payload business could re-rate value multiples dramatically.
* **First movers in space logistics**: As the number of small satellites, constellations, and on-orbit servicing demand grows, providers like MNTS may become essential “space infrastructure” nodes rather than niche players.
If MNTS can execute on its technical roadmap, deliver reliable OSV missions, and land recurring payload / servicing contracts, it could rebase itself as a backbone in space logistics.
Bull Case Summary
If management can:
1. Successfully demo Vigoride / follow-on OSVs with high reliability
2. Win a steady stream of contracts (NASA, defense, commercial)
3. Grow hosted payload revenue and in-orbit service margins
4. Maintain liquidity and avoid crippling dilution
Then MNTS could see a **multi-bagger re-rating**. Even partial execution (e.g. one major mission, a steady contract pipeline) could unlock several times current share value, given the large disconnect between *intrinsic infrastructure potential* and its current micro-cap valuation.
# $MIST - Price Target: $5.00 (2.5x)
What is MIST?
**Milestone Pharmaceuticals, Inc. (Ticker: MIST)** is a biopharmaceutical company focused on **developing and commercializing cardiovascular medicines**, with its lead candidate being **etripamil** (also referred to as CARDAMYST™) — a nasal spray, rapid-onset calcium channel blocker for **paroxysmal supraventricular tachycardia (PSVT)**. 
Their strategy is relatively lean: minimize overhead, focus capital on advancing regulatory approval and commercial launch, and use partnerships/licensing where possible.
Recent Developments & Catalysts
* **FDA CRL & Response Accepted**: MIST received a Complete Response Letter (CRL) from the FDA focused on **chemistry, manufacturing, and controls (CMC)** issues (not on clinical safety/efficacy).Their response to the CRL was accepted, and a new PDUFA target date was set for **December 13, 2025**. 
* **Capital Raise / Offering**: In mid-2025, MIST priced a public offering to raise \~$52.5 million (common stock + pre-funded warrants + Series A & B warrants) to fund clinical development, commercialization of etripamil, and general corporate purposes. 
* **Royalty Deal Extension / Support Funding**: They extended a $75 million royalty purchase agreement with RTW Investments through December 2025, helping provide financial backing toward launch readiness. 
* **Analyst Sentiment & Targets**: Some analyst coverage assigns a **“Strong Buy”** rating, with 12-month targets in the $6+ range (implying significant upside from current levels).
* **Lean Operating Model / Low Overhead**: MIST emphasizes cost efficiency, a small team (\~33 employees) and targeted spending focused on the lead program.
Why It Matters
* **Disproportionate Upside from Single Molecule Success**: Etripamil (if approved for PSVT) addresses an unmet need with few fast-acting self-administered options. Because MIST is essentially “all in” on this one drug, success could yield massive re-rating.
* **Regulatory/Catalyst Risk Reward Skew**: The CRL was not about clinical efficacy, so if the remaining CMC / manufacturing issues are resolved, approval is more a matter of execution vs. novel biology.
* **Funding Bridge**: The recent capital raise gives the company a longer runway to push through approval and initial commercialization phases.
* **Market Underappreciates Value**: The current market cap is relatively modest compared to what a successful drug launch and royalty / licensing potential could imply.
* **Multiple Shots at Expansion**: Beyond PSVT, etripamil has been studied (or is intended to be studied) for other cardiovascular arrhythmia indications (e.g. atrial fibrillation, rapid ventricular rate). 
Bull Case Summary
If Milestone can:
1. **Address the CMC / manufacturing issues** identified in the CRL competently,
2. Achieve **FDA approval** of etripamil for PSVT by the December 2025 target,
3. Successfully **commercialize / deploy the product** with payer reimbursement, physician adoption, and marketing,
4. Expand into **additional arrhythmia indications** or licensing deals, and
5. Manage dilution / capital structure prudently (i.e. avoid over-dilution),
then MIST could see a **major upside re-rating**. Even incremental wins — e.g. FDA acceptance of a resubmission, or signaling by payers / cardiology societies — could catalyze a multi-bag move from current levels.
# Remember: be fearful when others are greedy, and greedy when others are fearful.
Good luck to everyone next week!

Well folks I hope you have a wonderful weekend. I am done for the day! In case someone wants to do a bitt research over the weekend I recommend Os therapies, they published positive news today but they didn’t had much volume today. The company will participate in the Cancer Spotlight Panel at BioFuture 2025 on October 13, 2025 to present on OST-HER2 and its development plans. In addition , Analysts have maintained or reiterated “Buy” ratings on OSTX based on its clinical progress and regulatory strategy. OS Therapies (OSTX) will participate in the Daytime Emmy Awards in October 17, 2025. Just sending to those folks that want to do some research!

I think this is headed to at least $15. Look where Roth Capital (who manged the offering) moved WULF and our OS is only 18mil

Mein kleines Experiment, OS vs. KO und Faktor, leider heute schon grün, war eher was langfristiges, mal schauen ob ich übers Wochenende halte, habe mir noch kein Bild der Lage gemacht...
https://preview.redd.it/ygyhfaz45buf1.png?width=971&format=png&auto=webp&s=32e9c8e3ae358df7f94d533c839a84689e58dab7

I’ve been watching $COAI (ChainOpera AI) for a while now, and it’s been interesting to see how new Layer-1 projects like this can gain traction quickly. What caught my attention was the Bitget listing. Normally I’m careful with newly listed tokens, but $COAI’s combination of an experienced team, real AI use cases, and solid venture backing made me curious. The team isn’t just some random meme project—they’ve got actual tech, including a federated AI OS and marketplaces for AI agents.

Once $COAI went live on Bitget, I started noticing the early post-listing momentum. It wasn’t just hype; the community response, order book activity, and timing lined up in a way that’s been rare lately. The token is trading on BNB Chain and seems to have a lot of on-chain utility, so it’s more than just a memecoin play. I also like that Bitget gives tools for new listings that let people participate in events and rewards without being overwhelmed by complicated pre-sale rules.

This feels like a good example of how careful research combined with early exchange listings can give people an edge if they’re patient and strategic. I’m curious if others here track new Layer-1 listings this way, or if most people just chase meme hype. $COAI isn’t just a small token it’s trying to build real infrastructure for AI agents, and seeing it debut on a platform like Bitget first makes the early traction even more interesting.

I’m not telling anyone to buy, but from a “CryptoMoonShots” perspective, it’s worth keeping on your radar if you’re looking at early-stage Layer-1 projects with potential upside. It’s a good reminder that not every opportunity is a meme, and some of these low-cap tokens actually have utility behind them.

What are you talking about? They have less than a third of the revenue of OpenAI (which is arguably a much better AI company and better positioned to create an AI OS) but nearly the same valuation.
You really need to stop buying Alex Karp's bullshit dude.

Not financial advice, just sharing one I’ve been watching closely.
AI narratives are heating up again, and $COAI looks like one of the few that actually has some structure behind it. ChainOpera AI is building its own Layer-1 optimized for AI inference and provenance, plus a federated OS that lets users co-create and own decentralized AI agents.
The team includes researchers with serious federated learning backgrounds, and they closed a $17M seed round backed by well-known investors. With BNB momentum helping the sector and the project recently getting more visibility through Bitget, the setup feels strong.
I’m treating this as a mid-term bet on the AI + blockchain crossover narrative. Curious if anyone else sees this as a real play or just another hype cycle forming?

Man... Do you read any DD? Here's a free one. We're going to see everyone and their dogs make AI agents, but their agents won't be able to automate across ecosystems. Microsoft automates within its family of applications, but can't automate inside Salesforce, SAP or Google. These giants are often rivals so they don't play well together. $PATH is a neutral entity. They all love working with $PATH and don't see any threat in doing so. $PATH sits on top of the software stack, with its orchestration engine, Maestro. $PATH understands people will use agents within specific platforms, but the Maestro orchestration can monitor and control them all. UiPath enhances interoperability between disparate software systems like no other vendor can. Most companies don't have a single OS. They have a Frankenstein of platforms stitched together. No one wants a bunch of agents littered all over the place doing God knows what. If a large enterprise wants one place to command control and monitor all their automations, $PATH is the logical choice.